GENESTRAT® AND VERISTRAT® TEST RESULTS
WITHIN 72 HOURS
ACTIONABLE, BLOOD-BASED GENESTRAT® AND VERISTRAT® TEST RESULTS WITHIN 72 HOURS
How does Biodesix® make molecular testing easier for your practice?
Biodesix Lung Reflex™ tests integrate real-time measurement of genomic and proteomic biomarkers to inform tumor mutation status and the impact of the patients’ immune response to their tumor. This innovative testing strategy is simple, easy, and fast for the office and for patients. Faster results and more comprehensive information expedites results and time to treatment.
Changing molecular testing for patients with NSCLC….one blood draw at a time
✓ Easy – using one blood draw, one order form and one combined kit minimizes confusion and streamlines patient result reporting and reimbursement support
✓ Clinically Relevant – actionable results inform rapid treatment decisions and prognostic conversations with patients
✓ Patient-focused – one simple blood draw saves patients the time, expense and risks associated with surgical biopsy
✓ Collaborative – reflex testing gives pulmonologists, pathologists, thoracic surgeons, and oncologists each an opportunity to expedite results and time to treatment
Biodesix Lung Reflex™ Blood-based Results in 72 Hours Expedite Time to Treatment for NSCLC Patients1
Biodesix Lung Reflex™ integrates GeneStrat® and VeriStrat® testing from one blood draw for real-time measurement of genomic and proteomic biomarkers. Biodesix Lung Reflex provides fast, blood-based results and saves tissue for other testing, such as the tissue-based PD-L1 expression test*.
For newly diagnosed patients with non-small cell lung cancer (NSCLC), GeneStrat testing detects actionable mutations to inform targeted therapies for NSCLC. Patients with EGFR positive results are candidates for targeted therapies. Patients with EML4-ALK, ROS1, RET or BRAF mutations are also targeted therapy candidates. Patients with EGFR negative results will reflex to VeriStrat testing to identify aggressive tumor growth and facilitate patient-physician conversations about treatment, prognosis, and care preferences.
Clinical data supports that patients with a VeriStrat Good result are likely to derive benefit from platinum-based therapy, while those with a VeriStrat Poor result are less likely to respond to platinum-based therapy. PD-L1 tissue results, available from multiple vendors, may be considered for these patients, depending on patient history and other factors. For patients who express PD-L1 at ≥50%, single-agent immunotherapy may be a lower toxicity option. For those who express PD-L1 at <50%, more aggressive treatment through novel therapies and combinations, such as a platinum doublet with immunotherapy (immunotherapy triplet), may be a treatment choice. Additionally, broad molecular profiling to identify rare mutations may present options for alternate therapies or clinical trials.
For monitoring progression on EGFR TKI therapy, GeneStrat provides sensitive EGFR T790M detection from blood, with no tissue re-biopsy needed. Patients with an EGFR T790M positive result are candidates for third generation EGFR-TKI therapy.
For monitoring progression of patients with EGFR negative results, VeriStrat provides important prognostic information and is also predictive of therapeutic benefit from EGFR-TKIs.
*PD-L1 tissue testing is not available through Biodesix. Testing can be conducted through multiple vendors; turnaround time for results may vary.
1. Bowling M, et al. (2016, September). Poster presentation: IASLC, CMSTO, Chicago, IL. Abstract 143. Poster PS01.16.